11 Best Performing Biotech Stocks So Far in 2025

8. argenX SE (NASDAQ:ARGX)

Year-to-Date Performance: 24.88% 

argenx SE (NASDAQ:ARGX) is strengthening its leadership in autoimmune therapies with the rapid expansion of Vyvgart, its flagship antibody-based treatment. Available in both intravenous and subcutaneous forms, Vyvgart has become a cornerstone therapy for generalized myasthenia gravis (gMG) and is now extending its reach into other autoimmune diseases, including immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP).

A major 2025 highlight for argenx SE (NASDAQ:ARGX) has been the launch of the Vyvgart subcutaneous prefilled syringe, which is quickly gaining traction as a more convenient alternative to infusions. Its adoption in CIDP has been especially strong, with more than 2,500 patients already receiving treatment this year. The formulation’s ease of use is accelerating uptake in the U.S., while additional approvals in Japan and Canada are expected by year-end, further broadening its global footprint.

Vyvgart’s success is positioning it as one of the fastest-growing biologics in gMG and beyond, with analysts projecting multibillion-dollar peak sales. Upcoming late 2025 and early 2026 readouts from Phase 3 trials in seronegative gMG, ocular and pediatric MG, and primary ITP could drive even broader label expansions and solidify its role as a standard of care.

Beyond Vyvgart, argenx SE (NASDAQ:ARGX)is advancing a diverse pipeline, including early-stage candidates such as empasiprubart, ARGX-109, and ARGX-119 for autoimmune and rare neuromuscular diseases. The business is also branching into new modalities through partnerships, including a recent collaboration with Unnatural Products to develop oral peptide therapies.